

Prediction of the human *in vivo* antiplatelet effect of S- and R-indobufen using population pharmacodynamic modeling and simulation based on *in vitro* platelet aggregation test

Yook-Hwan Noh¹, Sungpil Han¹, Sangmin Choe¹, Jin-Ah Jung¹, Jin-Ah Jung¹, Ae-Kyung Hwang² and Hyeong-Seok Lim^{1*}

¹Department of Clinical Pharmacology and Therapeutics, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea

²Pharmacokinetic and Pharmacogenetic Laboratory, Clinical Research Center, Asan Medical Center, Seoul 05505, Republic of Korea

*Correspondence: H. S. Lim; Tel: +82-2-3010-4613, Fax: +82-2-3010-4622, E-mail: mdhslim@gmail.com



Received 23 Nov 2018

Revised 11 Dec 2018

Accepted 12 Dec 2018

Keywords

Dosage scheme,
Indobufen,
In vitro,
NONMEM,
Platelet aggregation,
Population pharmacodynamics

pISSN: 2289-0882

eISSN: 2383-5427

Indobufen (Ibustrin®), a reversible inhibitor of platelet aggregation, exists in two enantiomeric forms in 1:1 ratio. Here, we characterized the anti-platelet effect of S- and R-indobufen using response surface modeling using NONMEM® and predicted the therapeutic doses exerting the maximal efficacy of each enantioselective S- and R-indobufen formulation. S- and R-indobufen were added individually or together to 24 plasma samples from drug-naïve healthy subjects, generating 892 samples containing randomly selected concentrations of the drugs of 0–128 mg/L. Collagen-induced platelet aggregation in platelet-rich plasma was determined using a Chrono-log Lumi-Aggregometer. Inhibitory sigmoid I_{max} model adequately described the anti-platelet effect. The S-form was more potent, whereas the R-form showed less inter-individual variation. No significant interaction was observed between the two enantiomers. The anti-platelet effect of multiple treatments with 200 mg indobufen twice daily doses was predicted in the simulation study, and the effect of S- or R-indobufen alone at various doses was predicted to define optimal dosing regimen for each enantiomer. Simulation study predicted that 200 mg twice daily administration of S-indobufen alone will produce more treatment effect than S-and R-mixture formulation. S-indobufen produced treatment effect at lower concentration than R-indobufen. However, inter-individual variation of the pharmacodynamic response was smaller in R-indobufen. The present study suggests the optimal doses of R-and S-enantioselective indobufen formulations in terms of treatment efficacy for patients with thromboembolic problems. The proposed methodology in this study can be applied to the develop novel enantio-selective drugs more efficiently.

Introduction

Indobufen (2-[*p*-(1-oxo-2-isoindollinyl)-phenyl]-butyric acid) belongs to the group of non-steroidal anti-inflammatory drugs, and inhibits thromboxane production and cyclooxygenase (COX)-dependent platelet aggregation. The reversible inhibitory effect of indobufen on platelet aggregation is effective for the prophylaxis of thromboembolic events in patients at risk and for the maintenance of graft patency.[1]

Copyright © 2018 Translational and Clinical Pharmacology
© It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).
© This paper meets the requirement of KS X ISO 9706, ISO 9706-1994 and ANSI/NISO Z.39.48-1992 (Permanence of Paper).

Reviewer

This article reviewed by peer experts who are not TCP editors.

Indobufen exists in the mixture of two enantiomeric forms, R and S in a 1:1 ratio. Although the racemic mixture (*rac*-indobufen) is commonly used in medical practice, the anti-platelet and anti-inflammatory activity of indobufen resides mainly in the S-enantiomer.[1,2] S-indobufen is approximately 2-fold more potent than the racemate in inhibiting the synthesis of cyclooxygenase products.[2,3] Administration of *rac*-indobufen to healthy volunteers[4] or patients with obliterative atherosclerosis[5] resulted in significantly lower serum levels of the S-enantiomer than the R-enantiomer. The R-enantiomer also shows anti-platelet aggregation effects, and is detected at high concentrations in the blood after administration of the indobufen racemate. Here, we explored the optimal dosage of R-indobufen and S-indobufen as a single therapeutic agent, respectively, in comparison to the predicted treatment outcomes on therapeutic dosage of *rac*-indobufen, 400 mg/day (200 mg twice daily) through Monte-Carlo simulation.

The aim of the present study was to characterize the anti-platelet effects of S- and R-indobufen using *in vitro* data modeling and evaluate the interaction between the two enantiomers using population modeling methodologies. In addition, the anti-platelet effect of each indobufen enantiomer at steady state at the recommended therapeutic dosage was predicted.

Methods

Subjects

Twenty four men were enrolled at Asan Medical Center (Seoul, Korea). All enrolled subjects were healthy Korean male volunteers aged 19–50 years who weighed >50 kg and were within 20% of the ideal body weight. The platelet aggregation test was performed in healthy subjects who were not taking any medications and who did not have bleeding disorders. None of the subjects had significant cardiac, hepatic, renal, pulmonary, neurologic, gastrointestinal, or hematologic disorders as determined by medical history and physical examination. The physical examination included assessment of vital signs, electrocardiography, and clinical laboratory test (hematology, blood chemistry, and urinalysis). Subjects with a history of smoking or alcohol abuse, or those using any over-the-counter drug within 7 days before the first study day (Day 1) were excluded.

All laboratory tests other than the platelet aggregation test were performed at the Department of Laboratory Medicine, Asan Medical Center (accredited by the Korean Association of Quality Assurance for Clinical Laboratories). The platelet aggregation test was performed at the Clinical Pharmacology Lab of Asan Medical Center. The Institutional Review Board of Asan Medical Center approved the study protocol (registration No.; S2009-0248-0001), and all procedures were performed in accordance with the Good Clinical Practice guidelines[6] and the Declaration of Helsinki and its amendments. All participants provided written, informed consent before the screening test for eligibility.

Blood sample collection

Approximately 100 mL whole blood was collected into standard sodium citrate tubes (3.8%) from each subject. Blood samples were centrifuged to obtain plasma for use in pharmacodynamic (PD) analysis.

Pharmacodynamic plasma sample analyses (Platelet Aggregation Inhibition Assay)

The plasma assay for determining *in vitro* platelet aggregation inhibition was performed using S- and R-indobufen (Ibustrin® tablet 200 mg) from Ildong Pharmaceuticals Co., Ltd. (Seoul, Korea). Each reference standard of S- and R-indobufen (0.5 g) was dissolved in methanol to generate a 10,000 mg/L solution, and then diluted using platelet-rich plasma (PRP) to produce 892 mixtures consisting of different concentrations of S- and R-indobufen. Basically, 0.25, 1, 2, 4, 8, 16, 24, 32, 64, and 128 mg/L of S-indobufen with corresponding 0 mg/L of R-indobufen, and vice versa were made using the plasma samples in each of 24 subjects. Then, the concentration combinations of S- and/or R-indobufen each that will be used in the experiment were randomly selected from 0.25, 1, 2, 4, 8, 16, 24, 32, 64, and 128 mg/L by generating random number using R software, and we conducted the experiment based on the preselected concentration combinations of S- and/or R-indobufen. The resultant final dataset used in this analysis consists of 366 and 364 “0” concentrations of S- and R- indobufen, and the other concentrations ranged from 36 and 48, respectively. Platelet aggregation inhibition was determined using a Four-Channel aggregometer (Chrono-Log 570VS Model, Chrono-Log Corp., Havertown, PA, USA) equipped with an AggroLink software package as described previously with modifications.[7] In brief, PRP and platelet-poor plasma (PPP) were prepared by differential centrifugation (200 g for 10 min and 2,345 g for 10 min at 25°C, respectively). The PRP (0.3 mL) was incubated at 37°C in the aggregometer for 5 min, followed by the addition of collagen (2 µg/mL) with continuous stirring. Platelet aggregation was recorded for up to 10 min and expressed as the maximal percentage change of light transmission from baseline using PPP as a reference, and maximal platelet aggregation (MPA) was calculated. Plasma samples from healthy male subjects were used for *in vitro* assessments. No study drug was administered to the subjects.

Pharmacokinetic data

Pharmacokinetic (PK) data were obtained from Glowka et al., who analyzed the steady state PK characteristics of indobufen enantiomers in a patient with obliterative atherosclerosis [5]. In that study, 200 mg indobufen was administered twice daily for 7 days to 11 patients (eight men and three women; 47–71 years of age [mean 60 ± 7 years], body weight 47–100 kg [mean 72 ± 17 kg]), and PK sampling and measurement of bleeding time were performed. The same PK parameters were used in the present simulation study to identify the optimal dosage regimen of S-

adequate to use in clinical situations (Fig. 1). Anti-platelet effect of each enantioselective indobufen was compared with the effect on 200 mg twice daily doses of *rac*-indobufen, which is a current therapeutic doses of indobufen. Monte-carlo simulation was conducted to evaluate the concentration-anti-platelet effect relationships of each R- and S-indobufen formulation. Then, anti-platelet effect was simulated on 200 mg twice daily dosing regimen of each *rac*-indobufen, S-indobufen, and R-indobufen using the average steady state concentration of S- and R-indobufen on 200 mg twice daily doses of *rac*-indobufen in a previous clinical study.[5]

Results

Study population

Of the 24 subjects enrolled, the mean (\pm standard deviation) age was 25.5 ± 3.2 years (range, 21–35 years) and the mean weight (\pm standard deviation) was 70.0 ± 6.4 kg (range, 56–69.5 kg).

Pharmacodynamic model

Various structural and error models were tested, guided by graphical assessment of optimum fit properties and statistical significance criteria. The inhibitory sigmoid I_{max} model was the most accurate for describing platelet aggregation inhibition data. When the concentration-platelet aggregation dataset was fit using response surface model without fixing the initial value of ISR (interaction between S- and R-form drug activities) as zero in NONMEM, the parameter estimate of ISR and its standard error were -0.647 and 0.432 , and its derived 95% confidence interval included a zero value. We assumed that there was no interaction between the two enantiomers, the interaction term (ISR) value was fixed at zero at the subsequent fittings.

Diagnostic plots revealed no significant bias, and no trend was observed (Fig. 2). The final model was validated using predictive check (Fig. 3) and nonparametric bootstrap procedures

(Table 1). The final parameter estimates are shown in Table 1.

Monte-Carlo simulation

Simulation study suggested that *rac*-indobufen 200 mg twice daily doses, a current therapeutic dose is not enough to produce maximal anti-platelet effect. 200 mg twice daily administration of S-indobufen alone was predicted to produce more treatment effect than *rac*-indobufen. S-indobufen exerted its maximal effect from a lower plasma concentration (>40 mg/L) than R-indobufen (>140 mg/L). However, the inter-individual variations of the relationship between the plasma concentration and the anti-platelet effect was smaller in R-indobufen (Fig. 4).

Discussion

The present study characterized the anti-platelet effect of S- and R-indobufen by PD modeling of *in vitro* data and then predicted the human responses through Monte-Carlo simula-




Figure 3. Response surface plot for model predicted median versus observed (black circle) maximum platelet inhibition on various combination of R- and S-indobufen.




Figure 2. Diagnostic plots of the final *in vitro* PD model. Left, observed vs. predicted (open circles: individual prediction, filled triangles: population prediction). Right, population predicted vs. conditional weighted residuals (CWRES).

Table 1. Population parameter estimates and bootstrap results for the final pharmacodynamic model

Parameter	Estimate	RSE (%)	Median	2.5, 97.5 th percentile
$C_{50, S}$	6.75	26.8	5.66	3.41, 10.34
$C_{50, R}$	48.7	3.6	48.33	44.45, 51.90
γ	2.54	11.5	2.55	1.96, 3.66
I_{max}	6.38	28.8	8.52	4.66, 13.76
Inter-individual variability (CV, %)				
IIV of $C_{50, S}$	200.1	13.4	195.2	121.5, 266.0
IIV of $C_{50, R}$	8.4	85.8	7.2	0.3, 14.3
IIV of γ	45.5	26.0	44.2	25.8, 75.1
IIV of I_{max}	98.4	43.1	86.9	52.1, 144.3
Residual variability (%)				
ϵ (additive)	12.10	7.2	12.08	10.59, 13.88

Abbreviations: *RSE*, relative standard error (standard error divided by the parameter estimate); *IIV*, inter-individual variability; I_{max} , maximal inhibitory effect; C_{50} , concentration at half- I_{max} ; γ , shape factor of sigmoid E_{max} model. ϵ (additive) represents the standard deviation.




Figure 4. Simulated pharmacodynamic effect of R- and S-indobufen. The black horizontal dotted line indicates the median predicted maximal platelet aggregation (MPA) on multiple dosing of indobufen at 400 mg/day, which is 35.60 % and was obtained from Monte-Carlo simulation using the average steady state concentrations of S- and R-indobufen in a literature[5] and the PD model constructed in this study; The blue horizontal dotted line indicates the median MPA on multiple dosing of R-indobufen only at 200 mg/day, which is 11.90 % and was obtained from Monte-Carlo simulation using the clearance of R-indobufen in a literature[5] and the PD model; The gray horizontal dotted line indicates the median MPA on multiple dosing of S-indobufen only at 200 mg/day, which is 7.58 % and was obtained from Monte-Carlo simulation using the clearance of S-indobufen in a literature[5] and the PD model. *Platelet aggregation was determined using a Chrono-log Lumi-Aggregometer as the percent change from the baseline.

tion using the PD model and human PK data from a literature. Response-surface model was applied to evaluate the anti-platelet effect of both S- and R-indobufen simultaneously. The effect of indobufen was well-described by the inhibitory sigmoid I_{max} model with no significant interaction between S- and R-indobufen. Based on the final PD model, Monte Carlo simulation was performed to predict the optimal dosing regimens for S- and R-indobufen as a single formulation.

Indobufen is a selective inhibitor of cyclooxygenase activity in human platelets, and this inhibitory effect is mainly attributed to the S-enantiomer of the drug. S-indobufen is known to be twice as potent as racemic indobufen in inhibiting platelet ag-

gregation and thromboxane formation.[2] In the present study, S-indobufen was found to be 7.2-fold more potent than R-indobufen (Table 1). However, R-indobufen can inhibit the same enzyme at higher concentrations.[2] Large inter-individual variability in the anti-platelet effect indicates that the development of a pure enantioselective indobufen is worthwhile. While S-indobufen is more potent than R-indobufen, R-indobufen has more favorable characteristics in terms of unexplainable inter-individual variability, which indicates the size of uncertainty in the anti-platelet effect when prescribed, as can be seen in the estimated inter-individual variability was 200.1% (in CV) for S-indobufen and 48.4% for R-indobufen (Table 1). The simulated

95% prediction interval was much wider in S-indobufen than in R-indobufen (Fig. 4). As shown in Figure 4, the maximal inhibitory effect was achieved approximately at >40 mg/L for S-indobufen, and >140 mg for R-indobufen. Those concentrations correspond to about 500 mg, twice daily dose for S-indobufen, and 1,000 mg, twice daily dose for R-indobufen based on steady state concentration of R- and S-indobufen on *rac*-indobufen in a previous study[5] and the assumption of linear PK. The doses are relatively high considering the current therapeutic doses of *rac*-indobufen. Therefore, To develop the enantioselective indobufen formulations, the tolerability at the doses should be evaluated at the beginning of the clinical development.

The present study had several limitations. The simulation was performed using *in vitro* and a literature data. Therefore additional clinical data including human *in vivo* PK/PD data are required to validate these results. The sample size was also small and clinical covariates has not been screened due to the homogeneity of the study population.

Conclusions

The present study characterized the anti-platelet effect of indobufen using population PD modeling and simulation analysis. The effect of indobufen was well-described by the inhibitory sigmoid I_{max} model in the response-surface model. S-indobufen was more potent than R-indobufen, while the inter-individual variability was smaller in R-indobufen than S-form. The simulation predicted concentrations for maximal therapeutic effect is >140 mg/L for R-indobufen and > 50 mg/L for S-indobufen. The present methodology can be applied to the develop novel enantio-selective drugs more efficiently.

Acknowledgments

The authors would like to thank the Clinical Trial Center staff at Asan Medical Center for technical assistance associated with the clinical study. This study was supported by the Technology Innovation Program (grant numbers: 10067737, Establishment of risk management platform with aim to reduce attrition of new drugs and its service) funded by the Ministry of Trade, Industry & Energy (MI, Korea), and by a grant of the Korea Health Technology R&D Project through the Korea Health

Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HI14C1090).

We thank Dr. Joon Seo Lim from the Scientific Publications Team at Asan Medical Center for his editorial assistance in preparing this manuscript.

Conflict of interest

- Authors: The authors declare that they have no conflict of interests
- Reviewers: Nothing to declare
- Editors: Nothing to declare

References

1. Bhana N, McClellan KJ. Indobufen: an updated review of its use in the management of atherothrombosis. *Drugs Aging* 2001;18:369-388.
2. Patrignani P, Volpi D, Ferrario R, Romanzini L, Di Somma M, Patrono C. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. *Eur J Pharmacol* 1990;191:83-88.
3. Glowka FK, Karazniewicz M. Resolution of indobufen enantiomers by capillary zone electrophoresis. *Pharmacokinetic studies of human serum. J Chromatogr A* 2004;1032:219-225.
4. Glowka FK. Stereoselective pharmacokinetics of indobufen from tablets and intramuscular injections in man. *Chirality* 2000;12:38-42. doi: 10.1002/(SICI)1520-636X(2000)12:1<38::AID-CHIR7>3.0.CO;2-O.
5. Glowka FK, Strzelecka D, Zapalski S. Steady-state pharmacokinetics of indobufen enantiomers in patients with obliterative atherosclerosis. *Chirality* 2001;13:308-312. doi: 10.1002/chir.1036.
6. Korea good clinical practice (KGCP) [in Korean]. <http://www.law.go.kr/lsSc.do?menuId=0&p1=&subMenu=1&query=%EC%95%BD%EC%82%AC%EB%B2%95+%EC%8B%9C%ED%96%89%EA%B7%9C%EC%B9%99&x=0&y=0#AJAX> Accessed 20 March 2013
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, et al. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. *Blood Coagul Fibrinolysis* 2004;15:427-433.
8. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. *J Pharmacokinet Biopharm* 1992;20:511-528.
9. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. *J Pharmacokinet Pharmacodyn* 2001;28:231-252.
10. Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL. Response surface model for anesthetic drug interactions. *Anesthesiology* 2000;92:1603-1616.
11. Gabrielsson J, Weiner D. *Pharmacokinetic/pharmacodynamic data analysis: Concepts and applications*. Swedish Pharmaceutical Press, 2000